Strategic Initiative

Slingshot members are tracking this corporate initiative:

Allergan (AGN) and Novartis (NVS) Announce Collaboration for Phase 2b Trial Evaluating AGN's Cenicriviroc with NVS' Farnesoid X Receptor (FXR) in Non-Alcoholic Steatohepatitis (NASH)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Apr 18, 2017
Projected Implementation:
Q2, 2017
Relevance Tracked Until:
Q2, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Nash, Non-alcoholic Steatohepatitis, Cenicriviroc, Farnesoid X Receptor, Fxr